Tonix Pharmaceuticals
TNXP
16 hedge funds and large institutions have $158K invested in Tonix Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 7 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
23% more funds holding
Funds holding: 13 → 16 (+3)
0.04% less ownership
Funds ownership: 0.05% → 0.01% (-0.04%)
31% less capital invested
Capital invested by funds: $227K → $158K (-$69.6K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$145K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$96.7K |
| 3 |
VF
Virtu Financial
New York
|
+$54.8K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$40K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
+$16.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Prudential Financial
Newark,
New Jersey
|
-$68.1K |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$43.6K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$39K |
| 4 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$19.6K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$17.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HF
26
HRT Financial
New York
| – | -$15K | -215 | Closed |
|
27
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$210 | -3 | Closed |
|
|
NL
28
NVWM LLC
Yardley,
Pennsylvania
| – | -$3 | – | – |
|
|
CAL
29
Capital Advisors Ltd
Shaker Heights,
Ohio
| – | +$322 | +8 | New |
|
TNXP Hedge Fund Activity: Q3 2024 in Review
16 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Tonix Pharmaceuticals (TNXP) for Q3 2024, worth a combined $158K — down 31% from $227K a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new TNXP positions and 7 closed out — a net gain of 3 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $145K. The largest seller was Prudential Financial, exiting entirely with an estimated $68.1K sold.
- 16 institutional investors held Tonix Pharmaceuticals (TNXP) as of Q3 2024, up from 13 in Q2 2024.
- Funds reported $158K of Tonix Pharmaceuticals stock for Q3 2024, down 31% quarter-over-quarter.
- 10 funds opened new Tonix Pharmaceuticals positions in Q3 2024 and 7 closed out, a net change of +3 holders.
- The largest Tonix Pharmaceuticals buyer in Q3 2024 was Millennium Management, an estimated $145K added.
- The largest Tonix Pharmaceuticals seller in Q3 2024 was Prudential Financial, an estimated $68.1K sold.
Based on aggregated 13F filings for Q3 2024.